Results of preclinical studies related to the therapeutic implementation of SHH proteins or activation of the SHH signaling pathway beneficially improved in several ischemic disease models such as AMI [15,43], myocardial ischemic—reperfusion, HLI [17,23,45,74], stroke [75], diabetic wound healing [44], skeletal myogenesis [76], osteogenesis and bone tissue formation [77] Table 2. This evidence concerns the gene SHH and ischemic disease.